Sanguedolce R, Flandina C, Cucchiara T, Varvara F, Rausa L
Istituto di Farmacologia, Policlinico P. Giaccone, Palermo, Italy.
Res Commun Chem Pathol Pharmacol. 1993 Oct;82(1):81-9.
CD1 female mice were treated with doxorubicin (DXR, 5 mg/Kg i.v.) once a week for eight weeks or with lonidamine (LND, 100 mg/Kg i.p.) once a week for eight weeks. Other mice received lonidamine (100 mg/Kg i.p.) immediately before doxorubicin (5 mg/Kg i.v.) administration. The animals were sacrificed four weeks after the last administration and their cardiac morphology was evaluated by means of light microscopy. Lonidamine slightly reduced the extent of the atrial but not of the ventricular alterations caused by DXR. The results seem to indicate that, in this experimental model, lonidamine does not substantially modify the cardiotoxicity induced by doxorubicin.
CD1雌性小鼠每周静脉注射一次阿霉素(DXR,5毫克/千克),持续八周;或每周腹腔注射一次氯尼达明(LND,100毫克/千克),持续八周。其他小鼠在静脉注射阿霉素(5毫克/千克)前立即腹腔注射氯尼达明(100毫克/千克)。在最后一次给药四周后处死动物,通过光学显微镜评估其心脏形态。氯尼达明略微减轻了由阿霉素引起的心房改变程度,但未减轻心室改变程度。结果似乎表明,在该实验模型中,氯尼达明并未实质性改变阿霉素诱导的心脏毒性。